AtriCure gets FDA OK for ablation device

AtriCure said that the Food and Drug Administration granted marketing clearance to its Isolator Synergy bipolar ablation system for the ablation, or scarring, of soft tissue. AtriCure said the device is not cleared for use on heart tissue. The company expects to launch the device during the third quarter.